NEW YORK (GenomeWeb News) – Singapore cancer diagnostics firm Clearbridge BioMedics announced on Wednesday the closing of a Series B financing round, bringing in S$9.0 million (US$7.2 million).

The financing will be used to further develop Clearbridge's ClearCell System, a non-biomarker-based platform for detecting, isolating, and retrieving circulating tumor cells from blood. The system consists of the ClearCell unit and single-use microfluidic biochips called CTChips.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.